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Singapore Company Promises Dialysis Treatment Breakthrough
Published: June 04, 2008 in Knowledge@SMU 
If all goes well, two years from now kidney patients will get a new lease of life when a portable, artificial kidney is
launched by a Singapore-based company. AWAK Technologies was formed in 2007 to commercialise a technology
that allows people suffering from kidney failure to lead a life that is close to normal under the circumstances. This
technology will allow patients to undergo dialysis while on the go without much human intervention required.
“The best solution is the artificial kidney because it enhances the quality of life,” said Neo Kok Beng, CEO of AWAK
Technologies, speaking recently on “Disrupting the Kidney Dialysis Market: Revolutionary Technologies & Business
Models” at a CEO Talks forum organised by the Wee Kim Wee Centre, Singapore Management University. Neo is a
Fellow of Institution of Engineers, Singapore. He was also a former vice president, in charge of new businesses, at
Singapore Technologies Electronics where he established and headed Incubators@Work (mailto:Incubators@Work)!,
the Singapore Technologies Intrapreneurship Programme.
Neo explained that about 80% of people who suffer from kidney failure in Singapore undergo a treatment called
haemodialysis which requires them to attend a dialysis centre for treatment every two days. This limits the ability of
the sufferer to travel and, sometimes, even to find work.
Transplants are often touted as the ultimate solution but they are not for everyone. There are many more sufferers
than there are kidneys to go around. In addition, transplants carry the risk of infection and tissue rejection.
Global Business Potential
In April 2007, AWAK Technologies was formed to commercially develop an artificial kidney. AWAK stands for
Automated Wearable Artificial Kidney. The company’s vision is to enable patients to lead normal lives again with the
use of an artificial, wearable kidney. There are currently no such products on the market. The founders of AWAK,
nephrologists Gordon Ku, David Lee and Martin Roberts saw the technology as being revolutionary because it solved
many of the problems with existing dialysis treatment, and thus had tremendous commercial potential.
Treating kidney disease is big business. According to research analysts, globally, End Stage Renal Disease (ESRD) is
worth US$55 billion and is growing at 8% per year. This is a large market and can only get larger as people in the
emerging markets of India and China become wealthy enough to afford treatment. As a result, AWAK Technology has
been working hard to develop a viable commercial product.
The company began by buying the worldwide exclusive rights to the patent which had originally been filed by the
University of California, Los Angeles. The patent describes a wearable, dialysis device that operates based on
peritoneal dialysis. This is where the peritoneal membrane surrounding the intestines acts as a filter and extracts
waste products such as urea and potassium that the kidneys are unable to process.
The Technology
Peritoneal dialysis is the other form of dialysis treatment apart from haemodialysis. In Singapore, about 20% of ESRD
sufferers currently rely on peritoneal dialysis. Peritoneal dialysis can be done at home or at the workplace rather
than a dialysis centre. This is an improvement over haemodialysis because it gives patients more freedom to work
and travel. However, there are disadvantages. Peritoneal dialysis requires tremendous self-discipline on the part of
patients who have to do the dialysis regularly themselves. In addition, they have to ensure a high level of
cleanliness each time as the dialysis fluid is exchanged several times a day.
Unlike existing peritoneal dialysis treatments, AWAK’s artificial kidney would be wearable and would also automate
the exchange of dialysis fluids, thus making the treatment more convenient for sufferers. With the exchange process
automated, there is no need to rely on the patient’s self discipline to do the dialysis. And because the artificial
kidney is worn all the time, keeping it clean becomes much easier. Neo is confident that the artificial kidney is a
significant step forward for dialysis treatment. “The artificial kidney increases the quality of life and earning
capacity,” he said.
The company has already begun working on the prototype and clinical trials are expected to begin in July 2008 at
the Singapore General Hospital. The clinical trials are expected to be completed by June 2009. If successful, the
product will be launched in January 2010. Interestingly, AWAK is based in Singapore rather than in the US where the
patent was originally filed. About half the board is based in Singapore, including Neo and the company’s chairman, Dr
Gordon Ku, who is the founder and chairman of the Kidney Dialysis Foundation.
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According to Neo, Singapore was chosen because product development is expensive in the United States. Singapore
is also a good location because of its strong protection of intellectual property, and because the product will
eventually be manufactured in Asia. AWAK is currently looking at a manufacturer in Malaysia as a possible
manufacturing partner.
Responding to concerns about the ethics of profiting from disease, Neo responded that the company was set up to
be profit-making. As such, its goal was not to make dialysis more affordable but to provide better treatment at the
same price. The profits of the company could be channelled into a foundation to help the needy. “The company has
to be profitable first,” he said, before others can be helped. Neo said that the challenge for the company now was
to build the prototype. “You need to find the right raw materials at the right cost, and you need to design the
prototype in such a way that it meets regulatory requirements.”
Because the medical sector is heavily regulated, the design of the product and the company’s regulatory strategy is
very tightly bound, he said. The challenge is to build on an existing product in the market that has already been
approved. A completely new product, with no precedents, will take much longer to gain approval -- possibly up to
eight years -- whereas AWAK is hoping to commercialise the artificial kidney in two years.
Regulatory Requirements
Helping companies commercialise their technology is not new for Neo. He previously worked for Singapore
Technology, specialising in new products and new businesses in the areas of information security, telematics,
portable digital/computing devices and biomedical systems and services.
Comparing information technology and medical technology, Neo said that IT was much more straightforward. “With
IT, the regulatory requirements are not so onerous. There is no need for tedious trials. “With medical devices, the
regulators are very meticulous. There are more processes to go through and much more certification is required.”
He noted that for IT, there were standards-setting bodies such as the Institute for Electrical and Electronics
Engineers (IEEE). Because of these standards, all you have to do is develop your product and ensure that it adheres
to this standard for it to be accepted globally. However, no such global body exists to lay down the standard for
medical devices.
All medical devices have to be certified by different countries before they can be sold in that country. Even though
the US Food and Drug Administration (USFDA) has extensive and stringent certification requirements, FDA approval
only applies to products sold in the US. To sell a medical device in other countries, manufacturers need to submit
the product for certification by the relevant body in that country.
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